Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections

Ivan I. Tokin, Vladimir V. Nikiforov, Pavel I. Shabalkin, Pavel V. Pimanchev, Julia A. Isakova, Valeriy V. Tsvetkov

International Journal of Biomedicine. 2018;8(4):327-332.   
DOI: 10.21103/Article8(4)_OA12
Originally published December 15, 2018  


Background: Influenza is a highly variable infection that can cause fatal complications. Universal approaches, such as general stimulation of the immune system to activate its natural antiviral capacities, seem to be a rational measure.
Methods: A total of 410 patients with influenza-like infections (ILI) were randomly assigned to one of three treatment groups and one control group. Interferon gamma (IFN-γ) was administered by intranasal introduction of 1 to 3 drops into each nostril 5 times per day daily for 5 days. The first dose of investigational medicine was given within 48h of the onset of the influenza-like symptoms. One drop of the solution contains 1,000 IU of active substance. All patients received basic complex therapy without any antiviral or immunomodulating agents. The patients were followed up for 7 days. Treatment efficacy was evaluated by the mean duration of symptoms (MDS), the period of viral antigen detection (VAD) measured after 1-2 and 4-5 days of treatment, and the incidence of complications. We used conventional indicators to evaluate the safety of IFN-γ in the treatment of ILI.
Results: The administration of 2 or 3 drops of IFN-γ in each nasal passage led to better outcomes manifested in the considerable (P<0.05) reduction of all acute respiratory symptoms, and therefore to a more rapid recovery. In these treatment groups, statistically significant decreases for MDS values, VAD period, and incidence of complications were registered. Intranasal IFN-γ in complex therapy of ILI was considered to be well tolerated and safe.

Influenza • interferon gamma • respiratory tract infection • antiviral capacities

1. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-89.  PubMed
2. Don ЕS, Emelyanova AG, Yakovleva NN, Petrova NV, Nikiforova MV, Gorbunov EA, et al. Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model. J Med Virol. 2017;89(5):759-766. doi: 10.1002/jmv.24717.  PubMed
3. Berri F, Haffar G, Lê VB, Sadewasser A, Paki K, Lina B, et al. Annexin V incorporated into influenza virus particles inhibits gamma interferon signaling and promotes viral replication. J Virol. 2014;88(19):11215-28. doi: 10.1128/JVI.01405-14. PubMed
4. Verhoeven D, Perry S, Pryharski K. Control of influenza infection is impaired by diminished interferon-γ secretion by CD4 T cells in the lungs of toddler mice. J Leukoc Biol. 2016;100(1):203-12. doi: 10.1189/jlb.4A1014-497RR. PubMed
5. Zhu Y, Mou Q, Zhao B, Luo H, Zhi Y, Lan L, Jiang Y. [Recombinant influenza A virus NS2 protein inhibits the production of interferon in lung tissues of infected mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(12):1615-9. [Article in Chinese].  PubMed
6. Theeten H, Mathei C, Peeters K, Ogunjimi B, Goossens H, Ieven M, Van Damme P, Cools N. Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. Viral Immunol. 2016;29(3):169-75. doi: 10.1089/vim.2015.0071. PubMed
7. Deeva EG, Sologub TV, Tikhonova EP, Krasnova EI, Konovalova NI, et al. [Clinical and laboratory characteristics of influenza in pregnant women in the epidemiological season of 2013-2014]. Epidemiologiya i Infektsionnye Bolezni. 2015; 20(5):4–10. [Article in Russian]
8. Knobler SL, Mack A, Mahmoud A, Lemon SM. The Threat of Pandemic Influenza: Are We Ready? Workshop Summary. National Academy of Sciences: Washington, DC; 2005.
9. WHO. Influenza virus infections in humans. October, 2018. https://www.who.int/influenza/human_animal_interface/ [Electronic resource]. (Reference date: November 07, 2018).
10. WHO Global Technical Consultation: global standards and tools for influenza surveillance. Geneva: World Health Organization; 2011. [Electronic resource]. http://apps.who.int/iris/bitstream/10665/70724/1/WHO_HSE_GIP_2011.1_ eng.pdf (Reference date: October 07, 2018).
11. Federal State Statistics Service. Rosstat. [Electronic resource]. http:// www.gks.ru (Reference date: November 06, 2018).
12. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476-92. doi: 10.1128/CMR.00097-12. PubMed
13. Olson ZF, Sandbulte MR, Souza CK, Perez DR, Vincent AL, Loving CL. Factors affecting induction of peripheral IFN-γ recall response to influenza A virus vaccination in pigs. Vet Immunol Immunopathol. 2017;185:57-65. doi: 10.1016/j.vetimm.2017.01.009. PubMed
14. Song L, Xiong D, Hu M, Kang X, Pan Z, Jiao X. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice. PLoS One. 2016 Mar 1;11(3):e0150678. doi: 10.1371/journal.pone.0150678. eCollection 2016. PubMed
15. Harrison P. Influenza or Influenza-like Illness: Does It Matter? Medscape Infectious Diseases February 16, 2018. [Electronic resource]. (Reference date: November 09, 2018).
16. Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, ey al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018;96(2):122-128. doi: 10.2471/BLT.17.194514. PubMed
17. Kuriakose T, Tripp RA, Watford WT. Tumor Progression Locus 2 Promotes Induction of IFN-γ, Interferon Stimulated Genes and Antigen Specific CD8+ T-Cell Responses and Protects against Influenza Virus. PLoS Pathog. 2015;11(8):e1005038.  PubMed
18. Hayney MS, Henriquez KM, Barnet JH, Ewers T, Champion HM, Flannery S, Barrett B. Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. J Clin Virol. 2017;90:32-37. doi: 10.1016/j.jcv.2017.03.003.  PubMed
19. Tomoda T, Morita H, Kurashige T, Maassab HF. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response.Vaccine. 1995;13(2):185-90. PubMed 
20. Jester BJ, Uyeki TM, Patel A, Koonin L, Jernigan DB. 100 Years of Medical Countermeasures and Pandemic Influenza Preparedness. Am J Public Health. 2018;108(11):1469-1472. doi: 10.2105/AJPH.2018.304586. PubMed
21. Plavinskiy SL, Shabalkin PA, Isakova JA. Budget impact analysis on the intranasal form of interferon-gamma. International Journal of Pharmaceutical Research. 2018;10(4):343-345. [Article in Russian].

Download Article
Received November 15, 2018.
Accepted December 11, 2018.
©2018 International Medical Research and Development Corporation.